3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
61
Stomach Neoplasms
10
HER2-positive Breast Cancer
7
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Inflammatory Breast Neoplasms
3
Breast Diseases
3
Brain Neoplasms
3
Pathologic Complete Response
2
Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Cardiotoxicity
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Relapsed Pediatric Solid Tumor
1
Pancreatic Neoplasms
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Invasive Breast Cancer
1
Intestinal Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Gastric Cancer
1
HER2-positive
1
HER2+ Early or Locally Advanced Breast Cancer
1
HER2+ Breast Cancer
1
HER2 Positive Breast Cancer
1
HER-2 Positive Gastric Cancer
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Feasibility
1
Interventions
sotorasib
1
abemaciclib
1
X-Rays
1
Trastuzumab
1
Rosuvastatin Calcium
1
Rifampin
1
Pharmaceutical Services
1
Midazolam
1
Itraconazole
1
Injections
1
High-Throughput Nucleotide Sequencing
1
Fulvestrant
1
Digoxin
1
Dextromethorphan
1
Data Collection
1
Catalytic Domain
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Solid Tumor, Adult
×
Trastuzumab
×
Clear all
NCT04092673
2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2
Unknown
30 enrolled